Sera Prognostics Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
SERA
- Share Price
-
$2.02
- (As of Friday Closing)
Sera Prognostics General Information
Description
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Contact Information
Website
www.sera.comCorporate Office
- 2749 East Parleys Way
- Suite 200
- Salt Lake City, UT 84109
- United States
Corporate Office
- 2749 East Parleys Way
- Suite 200
- Salt Lake City, UT 84109
- United States
Sera Prognostics Stock Performance
As of 13-Nov-2026, Sera Prognostics’s stock price is $2.02. Its current market cap is $79.9M with 39.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.02 | $1.98 | $1.56 - $3.85 | $79.9M | 39.8M | 26.1K | -$0.67 |
Sera Prognostics Financials Summary
As of 30-Sep-2026, Sera Prognostics has a trailing 12-month revenue of $96K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 39,005 | 72,997 | 226,256 | 143,378 |
| Revenue | 96 | 81 | 77 | 306 |
| EBITDA | (36,229) | (35,232) | (34,784) | (36,927) |
| Net Income | (33,472) | (31,928) | (32,898) | (36,242) |
| Total Assets | 79,980 | 101,933 | 72,575 | 95,441 |
| Total Debt | 3,273 | 2,339 | 840 | 1,858 |
Sera Prognostics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sera Prognostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sera Prognostics Comparisons
Industry
Financing
Details
Sera Prognostics Competitors (8)
One of Sera Prognostics’s 8 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| RareCyte | Venture Capital-Backed | Seattle, WA | ||||
| Biodesix | Formerly VC-backed | Louisville, CO | ||||
| BioGenex Laboratories | Corporation | Fremont, CA | ||||
| Insight Molecular Diagnostics | Formerly VC-backed | Nashville, TN |
Sera Prognostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sera Prognostics Patents
Sera Prognostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026169908-A1 | Compositions and methods for detecting multiple pregnancy complications | Pending | 06-Feb-2025 | ||
| WO-2025171174-A1 | Systems and methods for aggregating and presenting cohort information associated with a pregnancy | Pending | 06-Feb-2024 | ||
| EP-4829510-A1 | Biomarkers for predicting due date and time to birth | Pending | 18-Dec-2023 | ||
| WO-2025137134-A1 | Biomarkers for predicting due date and time to birth | Inactive | 18-Dec-2023 | ||
| EP-4479750-A1 | Biomarker panels and methods for predicting preeclampsia | Pending | 18-Feb-2022 | G01N33/689 |
Sera Prognostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sera Prognostics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
29.11 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Services
Subindustry
of 97
Rank
Percentile
Sera Prognostics FAQs
-
When was Sera Prognostics founded?
Sera Prognostics was founded in 2008.
-
Where is Sera Prognostics headquartered?
Sera Prognostics is headquartered in Salt Lake City, UT.
-
What is the size of Sera Prognostics?
Sera Prognostics has 72 total employees.
-
What industry is Sera Prognostics in?
Sera Prognostics’s primary industry is Diagnostic Equipment.
-
Is Sera Prognostics a private or public company?
Sera Prognostics is a Public company.
-
What is Sera Prognostics’s stock symbol?
The ticker symbol for Sera Prognostics is SERA.
-
What is the current stock price of Sera Prognostics?
As of 13-Nov-2026 the stock price of Sera Prognostics is $2.02.
-
What is the current market cap of Sera Prognostics?
The current market capitalization of Sera Prognostics is $79.9M.
-
What is Sera Prognostics’s current revenue?
The trailing twelve month revenue for Sera Prognostics is $96K.
-
Who are Sera Prognostics’s competitors?
Bio-Rad Laboratories, RareCyte, Biodesix, BioGenex Laboratories, and Insight Molecular Diagnostics are some of the 8 competitors of Sera Prognostics.
-
What is Sera Prognostics’s annual earnings per share (EPS)?
Sera Prognostics’s EPS for 12 months was -$0.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
